Previous close | 1.8700 |
Open | 1.8100 |
Bid | 1.8800 x 100 |
Ask | 1.8800 x 100 |
Day's range | 1.7600 - 1.8450 |
52-week range | 0.9700 - 5.1000 |
Volume | |
Avg. volume | 33,047 |
Market cap | 7.86M |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.2400 |
Earnings date | 18 Apr 2024 - 22 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 28.20 |
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced that it will present a poster at the National Comprehensive Cancer Network (NCCN) 2024 Annual Conference, which will be held April 5-7, 2024, in Orlando, Florida. NCCN 2024 Annual Conference – Orlando World Center Marriott
Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stag
A total of 18 patients have been dosed in the trial to date Company anticipates moving into Cohort 6 in Q2 2024 following standard safety review AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it has completed dosing in Cohort 5 of the ReSPECT-LM Phase 1 dose escalation